Explore the vast range of titles available.

The resistance among various microbial species (infectious agents) to different antimicrobial drugs has emerged as a cause of public health threat all over the world at a terrifying rate. Due to the pacing advent of new resistance mechanisms and decrease in efficiency of treating common infectious diseases, it results in failure of microbial response to standard treatment, leading to prolonged illness, higher expenditures for health care, and an immense risk of death. Almost all the capable infecting agents (e.g., bacteria, fungi, virus, and parasite) have employed high levels of multidrug resistance (MDR) with enhanced morbidity and mortality; thus, they are referred to as “super bugs.” Although the development of MDR is a natural phenomenon, the inappropriate use of antimicrobial drugs, inadequate sanitary conditions, inappropriate food-handling, and poor infection prevention and control practices contribute to emergence of and encourage the further spread of MDR. Considering the significance of MDR, this paper, emphasizes the problems associated with MDR and the need to understand its significance and mechanisms to combat microbial infections.

Maillard reaction produces flavour and aroma during cooking process; and it is used almost everywhere from the baking industry to our day to day life to make food tasty. It is often called nonenzymatic browning reaction since it takes place in the absence of enzyme. When foods are being processed or cooked at high temperature, chemical reaction between amino acids and reducing sugars leads to the formation of Maillard reaction products (MRPs). Depending on the way the food is being processed, both beneficial and toxic MRPs can be produced. Therefore, there is a need to understand the different types of MRPs and their positive or negative health effects. In this review we have summarized how food processing effects MRP formation in some of the very common foods.

Oxidative phosphorylation and glycolysis are the two truly major energy metabolism pathways in humans. While maximal oxygen uptake ( $$\\dot{V}{\\text{O}}_{{2}}$$ V˙O2 max) has been used for a century as a whole-body measure of maximal oxidative phosphorylation, there is no universally accepted, comparable measure of maximal glycolysis. However, already in 1984, Alois Mader introduced the maximal rate of lactate accumulation in mmol/kg/s related to active muscle weight (vLamaxmuscle) for his mathematical model of human exercise metabolism. In 1994, on the basis of a critical analysis of glycolytic tests at the time, Mader proposed a practical test of the maximal rate of lactate accumulation in mmol per litre of earlobe or fingertip blood per second, corrected for alactic time (talac), that is measured during an ~ 10–15-s all-out exercise test (vLamaxblood). The variant vLamaxblood differs from the original vLamaxmuscle, as it is normalized to 1 L of blood volume and is today measured as the maximal rate of blood lactate accumulation in mmol/L/s. To measure it, participants typically perform a 10–15-s all-out test followed by quantification of the rise of the blood lactate concentration from pre-test to the maximum after exercise. Some few seconds of a 10–15-s all-out test are “alactic” and should be subtracted from the work time to more accurately estimate the vLamaxblood. However, (1) glycolytic flux is unlikely to be truly maximal during an all-out exercise test, (2) peak glycolytic flux occurs only briefly, (3) there is no criterion for reaching the vLamaxblood, (4) there is no correction for lactate clearance in the time from exercise cessation to blood sampling, (5) there is no correction for ATP resynthesis by oxidative phosphorylation and (6) the talac correction is error-prone. Therefore, we propose the peak rate of lactate accumulation in mmol/L/s in arterialized earlobe or fingertip blood during an all-out exercise test lasting 10–15 s (vLapeak) as a simplified estimate of peak glycolytic rate analogous to the $$\\dot{V}{\\text{O}}_{{2}}$$ V˙O2 peak. In contrast to the vLamaxblood, the vLapeak is not corrected for talac. Modelling using Alois Mader’s model of human exercise metabolism suggests that (with everything else being the same) a higher vLamaxmuscle will (a) improve performance in events where a large part of the hydrolysed ATP is resynthesized by glycolysis, (b) cause a leftward shift of the lactate curve and (c) increase carbohydrate usage and accelerate glycogen depletion at a given exercise intensity. There is large potential for research on the validation and improvement of vLapeak tests for athletes, healthy sedentary individuals and patients. This research should improve estimation of vLamaxmuscle from vLapeak and experimentally test the modelling predictions of the effects of changes in vLamaxmuscle on exercise performance and fatigue.

Cell adhesion molecules play a significant role in cancer progression and metastasis. Cell-cell interactions of cancer cells with endothelium determine the metastatic spread. In addition, direct tumor cell interactions with platelets, leukocytes, and soluble components significantly contribute to cancer cell adhesion, extravasation, and the establishment of metastatic lesions. Clinical evidence indicates that heparin, commonly used for treatment of thromboembolic events in cancer patients, is beneficial for their survival. Preclinical studies confirm that heparin possesses antimetastatic activities that lead to attenuation of metastasis in various animal models. Heparin contains several biological activities that may affect several steps in metastatic cascade. Here we focus on the role of cellular adhesion receptors in the metastatic cascade and discuss evidence for heparin as an inhibitor of cell adhesion. While P- and L-selectin facilitation of cellular contacts during hematogenous metastasis is being accepted as a potential target of heparin, here we propose that heparin may also interfere with integrin activity and thereby affect cancer progression. This review summarizes recent findings about potential mechanisms of tumor cell interactions in the vasculature and antimetastatic activities of heparin.

Fungal biofilm infections have become increasingly recognised as a significant clinical problem. One of the major reasons behind this is the impact that these have upon treatment, as antifungal therapy often fails and surgical intervention is required. This places a large financial burden on health care providers. This paper aims to illustrate the importance of fungal biofilms, particularly Candida albicans, and discusses some of the key fungal biofilm resistance mechanisms that include, extracellular matrix (ECM), efflux pump activity, persisters, cell density, overexpression of drug targets, stress responses, and the general physiology of the cell. The paper demonstrates the multifaceted nature of fungal biofilm resistance, which encompasses some of the newest data and ideas in the field.

The unfolded protein response (UPR) of the endoplasmic reticulum (ER) is a classic cellular reaction to stress that helps restore ER homeostasis. However, growing evidence demonstrates that the main UPR effectors (Activating Transcription Factor 6 (ATF6), X-box Binding Protein 1 (XBP1s), and Activating Transcription Factor 4 (ATF4)) not only regulate canonical UPR target genes but also promote the transcription of genes encoding secondary transcription factors (TFs). These secondary TFs contribute to ER homeostasis maintenance and are involved in various physiological processes that extend beyond the traditional UPR. In this review, we examine the secondary TFs activated by UPR master regulators (UPR-TFs) and discuss their functional roles in different tissues and organs. We emphasize how these secondary TFs, controlled by their respective UPR-TFs, participate in stress responses, cell differentiation, embryonic development, circadian rhythms, metabolism, and other physiological processes. Furthermore, we explore common signaling pathways and tissue-and cellspecific regulatory mechanisms, highlighting convergence points where secondary TFs from different UPR branches intersect, indicating a more complex regulatory network. We also discuss the functions of these secondary TFs in the lungs, placenta, testis, uterus, pancreas, and liver, as well as during embryonic development and in pathological conditions. This study reveals biological activities that extend beyond the traditional roles of the UPR, providing a broader view of this signaling pathway and opening new avenues for future research.

Defective mitochondrial unfolded protein response (UPRmt) plays an important role in driving tumor growth and treatment resistance. Under physiological conditions, UPRmt preserves mitochondrial protein homeostasis and structure by inducing chaperones such as heat shock proteins (HSP60, HSP70, HSP10) and proteases like caseinolytic peptidase ATP-dependent, proteolytic subunit (ClpP), and Lon peptidase 1 (LONP1). However, dysfunctional UPRmt in cancer cells may allow them to tolerate mitochondrial damage and metabolic dysregulation and avoid cell death, thus promoting therapy resistance. Our current understanding of how transcriptional regulators such as activating transcription factor 5 (ATF5), C/EBP homologous protein (CHOP), and forkhead box protein O3a (FOXO3a), along with signaling circuits including ATF5-ATF4-CHOP, sirtuin 3 (SIRT3)–FOXO3a, and protein kinase B (AKT)-estrogen receptor alpha (ERα), coordinate detrimental forms of UPRmt activation in cancer cells remains limited. This review describes known interactions among mediators of the UPRmt pathway and how they may be dysregulated in cancer cells. We also explore how this altered stress response may provide avenues for therapeutic targeting.

Four decades ago, specialized chemotherapy regimens turned osteosarcoma, once considered a uniformly fatal disease, into a disease in which a majority of patients survive. Though significant survival gains were made from the 1960s to the 1980s, further outcome improvements appear to have plateaued. This study aims to comprehensively review all significant, published data regarding osteosarcoma and outcome in the modern medical era in order to gauge treatment progress. Our results indicate that published survival improved dramatically from 1960s to 1980s and then leveled, or in some measures decreased. Recurrence rates decreased in the 1970s and then leveled. In contrast, published limb salvage rates have increased significantly every recent decade until the present. Though significant gains have been made in the past, no improvement in published osteosarcoma survival has been seen since 1980, highlighting the importance of a new strategy in the systemic management of this still very lethal condition.

Chemokines play a critical role in regulating immune cell infiltration and their interactions with cancer cells in the tumor microenvironment (TME). Disrupted chemokine gradients influence immune cell recruitment and activation, as well as tumor cell proliferation, metastasis, and angiogenesis. By modulating these processes, chemokines shape the immune landscape of the tumor microenvironment, driving either immunosuppressive or immunostimulatory responses with corresponding pro- or antitumor effects. Dysregulated expression of chemokines and their receptors is strongly associated with tumor initiation, progression, and clinical outcomes. As a result, the chemokine receptor axis has gained prominence as a therapeutic target in cancer immunotherapy. This review explores chemokine expression profiles across various tumor types and their receptor-mediated interactions with immune cells. It also summarizes current strategies to therapeutically target chemokine signaling, both as standalone interventions and in combination with other treatment modalities.

The concept of acute-on-chronic liver failure (ACLF) has been widely accepted around the world since it was proposed nearly 30 years ago, but there are still no universal criteria for the definition and diagnosis of ACLF worldwide. In recent years, the key clinical features for describing ACLF, such as the underlying chronic liver diseases, acute intrahepatic or extrahepatic insults, acute hepatic decompensation, extrahepatic organ failure, short-term high mortality, and the reversible course of the disease, have gradually narrowed the differences and reached a consensus. The pathogenesis of ACLF has not been fully elucidated, and most relevant studies focus on systemic inflammation and immune dysfunction. In this review, we discuss the evolution in the clinical definition of ACLF during the last few years and suggest clear criteria for ACLF diagnostics. In addition, we summarize the current understanding of ACLF pathogenesis and review the latest therapeutic targets against this condition. Lastly, we present a novel experimental mouse model that has been proven to be instrumental for the assessment of novel potential therapies for ACLF.